Abstract
The complex and widespread family of integrin receptors is involved in numerous physiological processes, such as tissue remodeling, angiogenesis, development of the immune response and homeostasis. In addition, their key role has been elucidated in important pathological disorders such as cancer, cardiovascular diseases, osteoporosis, autoimmune and inflammatory diseases and in the pathogenesis of infectious diseases, making them highly important targets for modern drug design campaigns. In this review we seek to present a concise overview of the small molecule antagonists of this diverse and highly complex receptor family. Integrin antagonists are classified according to the targeted integrin receptor and are discussed in four sections. First we present the fibrinogen αIIbβ3 and the vitronectin αVβ3 receptor antagonists. The remaining selective integrin antagonists are examined in the third section. The final section is dedicated to molecules with dual or multiple integrin activity. In addition, the use of antibodies and peptidomimetic approaches to modulate the integrin receptors are discussed, as well providing the reader with an overall appreciation of the field.
Keywords: Integrin receptors, fibrinogen (αIIbβ3) receptor, vitronectin (αVβ3) receptor, fibronectin (α5β1) receptor, small molecule antagonists, dual/multiple antagonists
Current Medicinal Chemistry
Title: Small Molecule Antagonists of Integrin Receptors
Volume: 17 Issue: 22
Author(s): A. Perdih and M. Sollner Dolenc
Affiliation:
Keywords: Integrin receptors, fibrinogen (αIIbβ3) receptor, vitronectin (αVβ3) receptor, fibronectin (α5β1) receptor, small molecule antagonists, dual/multiple antagonists
Abstract: The complex and widespread family of integrin receptors is involved in numerous physiological processes, such as tissue remodeling, angiogenesis, development of the immune response and homeostasis. In addition, their key role has been elucidated in important pathological disorders such as cancer, cardiovascular diseases, osteoporosis, autoimmune and inflammatory diseases and in the pathogenesis of infectious diseases, making them highly important targets for modern drug design campaigns. In this review we seek to present a concise overview of the small molecule antagonists of this diverse and highly complex receptor family. Integrin antagonists are classified according to the targeted integrin receptor and are discussed in four sections. First we present the fibrinogen αIIbβ3 and the vitronectin αVβ3 receptor antagonists. The remaining selective integrin antagonists are examined in the third section. The final section is dedicated to molecules with dual or multiple integrin activity. In addition, the use of antibodies and peptidomimetic approaches to modulate the integrin receptors are discussed, as well providing the reader with an overall appreciation of the field.
Export Options
About this article
Cite this article as:
Perdih A. and Sollner Dolenc M., Small Molecule Antagonists of Integrin Receptors, Current Medicinal Chemistry 2010; 17 (22) . https://dx.doi.org/10.2174/092986710791698558
DOI https://dx.doi.org/10.2174/092986710791698558 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics of Multiple Sclerosis: Current Status and Potential Applications
Current Pharmacogenomics and Personalized Medicine Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design SV40 and HIV Sequences in the Cerebrospinal Fluid of a Patient with AIDS Dementia Complex
Current HIV Research Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Graphene-based Biosensors for Biomolecules Detection
Current Nanoscience CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Combined Transcriptomic and Proteomic Analyses of Cerebral Frontal Lobe Tissue Identified RNA Metabolism Dysregulation as One Potential Pathogenic Mechanism in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Current Neurovascular Research The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research “Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies
Current Drug Therapy Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Real-World Data Regarding Long-Term Administration of Natalizumab Derived from a Neurology Department along with Literature Review
CNS & Neurological Disorders - Drug Targets Autoimmune Neuromuscular Disorders
Current Neuropharmacology Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets